Huiqiang Huang

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Tadeusz Robak, Huiqiang Huang, Jie Jin et al. · New England Journal of Medicine · 2015 · 385 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma

Haijun Wen, Huajuan Ma, Qichun Cai et al. · Nature Medicine · 2018 · 76 citations

Medicine, Molecular Genetics, Oncology +14

High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer

Chunyan Lan, Xin Huang, Suxia Lin et al. · Cell and Tissue Research · 2013 · 64 citations

Medicine, Immunology, Oncology +17

A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma

Martin Dreyling, Constantine S. Tam, Michael Wang et al. · Future Oncology · 2020 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17